Cell and gene therapy | Life Sciences | Fieldfisher
Skip to main content

Cell and gene therapy

Cell and gene therapy (CGT) also known as advanced therapy medicinal products (ATMPs) is predicted to be the future of medicine.

CGT has the power to change the way we treat various chronic and life shortening illnesses that had previously been seen as incurable. With the paradigm potentially shifting from one of illness management to cure, CGT has the attention of the media, investors, regulators, pharmaceutical companies and the wider life sciences industry.

White paper – The future of medicine: Cell and gene therapy

In this paper we look at the cell and gene therapy landscape across key hotspots in Europe, examining the opportunities and challenges for those involved, particularly the regulatory and commercial law issues blocking the pathway from lab to patient. This paper also discusses how national healthcare providers across Europe are opening their eyes and pockets to the substantial cost-savings that CGT can provide and with this shift in approach, we look at what this means for the future of CGT in the UK and across the rest of Europe.